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Abstract
The review presents pediatric adverse drug events from a historical perspective and focuses on
selected safety issues associated with off-label use of medications for the psychiatric treatment of
youth. Clinical monitoring procedures for major psychotropic drug classes are reviewed. Prior
studies suggest that systematic treatment monitoring is warranted so as to both minimize risk of
unexpected adverse events and exposures to ineffective treatments. Clinical trials to establish the
efficacy and safety of drugs currently being used off-label in the pediatric population are needed. In
the meantime, clinicians should consider the existing evidence-base for these drugs and institute
close clinical monitoring.
Background
Most medications are approved for marketing based on
favorable benefit to risk assessments from clinical trial
data in adults. Pediatric medical practice has been prima-
rily off-label, i.e., permissible even though the drug was
not specified for this age group, or indication in the prod-
uct label approved by the Food and Drug Administration
(FDA) [1]. Off-label use of a drug is a common practice
representing approximately 50–75% of pediatric medica-
tion use [1]. In Europe, medication use may be character-
ized as either unlicensed, i.e. not approved for use in a
particular age group, or off-label, i.e. outside the terms of
their product license or marketing authorizations [2].
Occasionally, products not approved for use in children
have statements declaring inadequate data or have warn-
ings in their product label of potential dangers associated
with pediatric use. Being off-label does not constitute a
contraindication to the use of the product in children, so
practitioners are free to prescribe the drug. Fost, a pediatric
ethics expert, reminds clinicians that despite their fre-
quent use, such off-label treatments may be perceived as
"standard treatments" and lead individuals fearful of
experimental treatments in clinical trials to prefer these
inadequately evaluated but commonly used treatments
[3].
A Medline search since 1990 and a review of clinical text-
books in Pediatrics [4], Pharmacology [5], and Child Psy-
chopharmacology [6] were conducted to identify selected
safety issues representing important concerns in medical
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treatment. This paper reviews the safety of off-label pedi-
atric medications from two perspectives: an historical per-
spective that describes pediatric medication with
established risks which were identified after many years,
and a focused perspective on current psychopharmaco-
logic treatment, assessing the need and expectations for
adequate clinical monitoring. European experience with
clinical monitoring is described briefly as a comparison in
health systems predicated on a similar theoretical model
of psychiatry.
Historical examples from pediatric medicine
Off-label pediatric drug use has been based primarily on
extrapolation of efficacy, dosing, administration and side
effect profiles from adult studies. For treatments specific
to youth, particularly to the neonate, the evidence is most
often based on anecdote, case reports or open studies of
clinical experience. Yet, the history of pediatric pharma-
cology is rich with examples illustrating that newly mar-
keted drugs off-label for youth may have incomplete
adverse event profiles that require widespread community
utilization in such populations before uncommon or rare
serious adverse events are known [7]. This drug informa-
tion system does not well serve special populations, such
as children. Several cases illustrate the risks even for com-
monly used and accepted treatments.
The use of oxygen therapy to improve breathing for babies
in incubators was a widely accepted treatment as far back
as the 1930s. In the 1940s, increases in dosage and length
of exposure of oxygen were gradually accepted without
safety research. The incidence of retrolental fibroplasia
suddenly increased, followed by considerable debate in
the literature over the suggestion that prematurity itself
was responsible for the condition. Epidemiological data
suggested that the increase in retrolental fibroplasia's
adverse event rates following oxygen use varied by locale
and practice [8]. Yet it was not until 1952, more than a
decade later, that a definitive study linked increased oxy-
gen use with the development of retrolental fibroplasia
and blindness in premature babies [9].
The late '40s saw the introduction of chloramphenicol, an
important new antibiotic with the promise of effective-
ness in serious infections not controlled by available
drugs. Within a decade, however, increased use resulted in
the development of 'grey baby' syndrome in many of the
infants so treated. This devastating and lethal illness of
neonates, occurred due to inadequate enzymes to metab-
olize the drug to the glucuronide salt and then on insuffi-
cient renal filtration rate for excretion [10].
Recently marketed products also pose safety concerns for
children. For example, propofol, a sedative-hypnotic, was
marketed in 1989 in the U.S. and used for pre-anesthesia
induction. Trial data in children from 1988 showed it had
a 9% mortality rate in critically ill patients with upper res-
piratory tract infections compared with 4% for standard
sedatives, but causality was not established [11]. Since
then, propofol's use in pediatric intensive care units has
been linked with 'propofol infusion syndrome'. This syn-
drome induces hypotension and metabolic acidosis, and
produces a propofol metabolite that may induce toxicity
[12] or predispose patients to sepsis [13]. In the summer
of 2003, the FDA recommended a warning letter be sent
to doctors based on adverse event reports from MedWatch
(the FDA voluntary post-marketing surveillance reporting
system). This experience illustrates that the original rec-
ommendations for dosage and rate of administration
were not appropriate for all neonates and that the drug's
usage in clinical trials could not be generalized to longer
exposures or more rapid rates of titration in neonates
treated in the community [14].
Pediatric drug safety issues might be viewed narrowly as
simply the consequence of immature enzyme systems in
the neonate. But the history of pharmacology proves this
assumption wrong – elementary school age children can
also be at increased risk of adverse events [15] and can
experience problems distinctly different from adults
treated with the same drug. A good illustration is tetracy-
cline, a broad-spectrum antibiotic widely acclaimed and
enthusiastically prescribed when it was introduced in
1955. However, it would take 8 years for a definitive paper
to demonstrate that this antibiotic was responsible for
hypoplasia and staining of the enamel of primary and sec-
ondary teeth [16]. Children are at risk starting from uter-
ine exposure in the last trimester of pregnancy up to 8
years of age – the years of odontogenesis. In hindsight, the
structure of a chemically altered microbial metabolite
explains the loss of enamel through chelation of calcium
ions. Before this safety issue was recognized, several mil-
lion children were exposed to tetracycline with probably
few of the cases justifying the selection and use of this
drug.
Phenobarbital was introduced as an antiepileptic more
than 90 years ago. Currently, its long-term use in children
and adolescents is rarely justified because it is now known
to increase the risk of adverse cognitive and behavioral
events [17]. These effects include diminished intelligence
[18] and behavioral problems e.g., misconduct and
'hyperactivity' [19]. Phenobarbital continues to be used
for the control of simple febrile seizures and other sei-
zures of obscure etiology [20] in children despite the fact
that pronounced behavioral toxicity has been known for
more than 25 years [21]. Pharmacoepidemiologic data on
4.3 million youth (0–17 years) from across the U.S. and
with commercial health insurance illustrate this fact. In
2005, oral phenobarbital was dispensed to 0.025% ofChild and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
Page 3 of 11
(page number not for citation purposes)
youth (2,649), which was 7.4 times more likely in chil-
dren less than 2 years of age than their older counterparts
[22].
Promethazine is a phenothiazine type antihistamine used
in over-the-counter cough and cold products for the treat-
ment of allergic symptoms. FDA's recent Public Health
Advisory recommends avoiding use in children less than
2 years of age because of reports of serious and potentially
life-threatening respiratory depression [23]. This report
illustrates the gradual accrual of information for a cough
and cold medication marketed since the late 1970's to
update its safety profile [24].
This brief historical review of serious pitfalls in pediatric
drug safety suggests the need for reassessing and updating
the level of confidence required for prescribed drug use in
children. This is true for general medical conditions, but is
particularly true for the treatment of emotional and
behavioral disorders. The reasons behind this specific
emphasis include: 1) the rapid, expanded use of many
drugs for psychotherapeutic purposes, both singly and in
combination [25,26]; 2) the absence of current guidelines
for prescribing off-label psychotropic drugs and the need
to extend guidelines across physician specialties so that
both pediatricians and child psychiatrists (and other clini-
cal prescribers) follow appropriate standards of practice;
3) the absence of objective markers of emotional and
behavioral conditions which can limit solid decision-
making on the use of psychotropic medications; and 4)
the need for close clinical monitoring and the engagement
of parents and caregivers in such activities. The recent
actions of the FDA and other regulatory bodies regarding
antidepressant medication use in children make this need
all the more salient.
Historical examples from child mental health
The use of pemoline illustrates the challenges of drug
safety for youth. While early evidence of hepatotoxicity in
adults was recognized, the relatively low use in children
meant that a long (unexamined) safety experience would
accrue before a more definitive risk was recognized. After
21 years of modest usage in the treatment of attention-
deficit/hyperactivity disorder (ADHD), liver toxicity
including fatalities in youth were significantly associated
[27]. Warnings were added in 1996 and a black box warn-
ing was added in 1999 as well as new requirements for
written consent and biweekly liver enzyme monitoring.
Unfortunately, little empirical evidence could be found
that prescribers of pemoline were following this directive
[28]. In May 2005, Abbott Laboratories announced their
voluntary withdrawal of this drug from the U.S. market,
and the FDA finally withdrew approval of generic pemo-
line in November 2005, a full 6 years after the drug was
withdrawn in Canada [29].
Current pediatric psychopharmacologic safety concerns
The psychotropic treatment of youth has expanded sub-
stantially since 1990, a relatively short time period from a
population-based safety perspective [25]. In addition, sev-
eral major drug classes [e.g., selective serotonin reuptake
inhibitors (SSRIs) and atypical antipsychotics] represent
novel compounds (new molecular entities) introduced,
implying that much less information is known about their
safety profile at the time of marketing [30]. Data on atyp-
ical antipsychotic adverse effects in large community-
treated populations of adults are just beginning to emerge
[31] and data on youth are even rarer [32]. Because off-
label conditions increase the level of uncertainty regard-
ing a drug's safety, Table 1 and Table 2 differentiate psy-
chotropic drug use by their labeling status.
Changes in anticonvulsant pediatric usage in the past dec-
ade are largely attributed to their increased use for psycho-
therapeutic purposes, specifically as mood stabilizers
[33]. Fortunately, adverse events associated with anticon-
vulsant use in children have been widely studied, largely
as a result of the need for better treatments for seizure dis-
orders. Valproic acid was a welcome addition to the anti-
convulsant market in 1978. But soon after marketing, case
reports of serious events in children began to emerge.
Dreifuss and colleagues reviewed all U.S. reports of fatal
hepatic dysfunction received by the manufacturer in the
first six years of marketing. The large majority of these
reports (86.5%) involved use of another anticonvulsant in
addition to valproate. Age and combination use were
found to be the greatest risk factors for fatal hepatotoxic-
ity: children less than 2 receiving valproate as polytherapy
had a 20-fold greater risk compared to older ages [34].
While early data were narrowly interpreted as a risk asso-
ciated with immature liver enzyme metabolism of very
young children, subsequent reports revealed an elevated
risk among older children as well (3–10 years olds, espe-
cially those on polytherapy) [35]. A review of the world
literature revealed that more than 90% of the approxi-
mately 100 fatalities occurred in patients less than 20
years of age [35]. The risk of hepatotoxicity in youth
treated with multiple anticonvulsants which rely on liver
enzyme systems for their metabolism suggests that neu-
ropsychiatric concomitant drug regimens which also rely
on liver metabolism should be treated with special cau-
tion.
Psychotropic adverse events in youth
Table 3 shows selected major adverse events for both
recently approved and off-label psychiatric drug usage
with suggested safety surveillance monitoring in children
and adolescents. Whether the selected medications are
newly marketed or off-label, surveillance is appropriate
because exposed youth populations have been limited rel-
ative to adult populations [25]. Klein has advocated forChild and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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more rigorous post-marketing surveillance of adverse
events in psychiatry by using large commercial datasets
that would permit analysis of adverse event incidence
rates [36], an advantage over the existing FDA MedWatch
system. In the addition to a revised safety infrastructure, it
is critical that prescribing physicians perform careful, sys-
tematic clinical monitoring to avoid unnecessary risk [6].
Of the SSRIs, only fluoxetine has been shown to be effec-
tive for the treatment of depression in children and ado-
lescents [37,38]. However, the occurrence of suicidal
events in community-treated adults and in clinical trials
of adolescents which appeared shortly after the launch of
this new class of antidepressants [39,40] raised concerns,
but these were left unresolved by the FDA. Regulatory
events related to the pediatric use of SSRIs and suicidal
Table 1: Psychotropic drugs and FDA labeled psychiatric uses in youth.*
Class, Subclass Drug Age Limits, yr. Indication
Stimulants
Amphetamines 3+ ADHD; Narcolepsy
Methylphenidate 6+ ADHD; Narcolepsy
Modafinil 16+ Narcolepsy
Antidepressants
SSRI
Fluoxetine 8+ Depression
7+ OCD
Fluvoxamine 8+ OCD
Sertraline 6+ OCD
TCA
Clomipramine 10+ OCD
Doxepin 12+ Depression
Impiramine 6+ Enuresis
12+ Depression
Antipsychotics
Conventional
Chlorpromazine 6 (mo)-12 Severe Behavior Problems; Psychosis
Haloperidol 3+ Tourette's Disorder; Psychosis; Severe Behavioral Disorders
Thiothixene 12+ Psychosis
Loxapine 16+ Psychosis
Molindone 12+ Psychosis
Fluphenazine 12+ Psychosis
Trifluperazine 12+ Psychosis
Perphenazine 12+ Schizophrenia
Pimozide 12+ Tourette's Disorder
Prochlorperazine 2–12 Psychosis
Thioridazine 2+ Schizophrenia
Atypical
Aripiprazole 13+ Schizophrenia
10+ Acute and Mixed Mania
Risperidone 10+ Acute and Mixed Mania;
5–16 Irritability in Autism
13+ Schizophrenia
Miscellaneous
Atomoxetine 6+ ADHD
Chlordiazepoxide 6+ Anxiety
Clorazepate 10+ Anxiety
Desmopressin Oral 6+ Enuresis
Diazepam 6 months + Anxiety
Flurazepam 15+ Insomnia
Hydroxyzine < 6 Anxiety
> 6 Sedation
Lithium Carbonate 12+ Manic Episodes
Promethazine 2+ Sedation
*This information was current on March 12, 2008 based on the Physicians Desk Reference 2007 or FDA announcements. Readers should consult 
FDA guidelines for most current drug labeling.Child and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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risks in youth were initiated by Medicines and Healthcare
products Regulatory Agency (MHRA) in U.K. in 2003 and
rapidly produced a similar scenario in the U.S. in 2004,
culminating with a black box warning for all 3 classes of
antidepressants, namely SSRIs, tricyclic antidepressants
(TCAs) and Other antidepressants [41].
Other adverse events are more common with antidepres-
sants and may be useful in identifying who is at risk for
suicidal thoughts or attempts. For example, activation was
highlighted in the Hammad meta-analysis in association
with suicidal ideation or behavior [42]. Unfortunately,
the timing of this symptom was not available in relation
to the adverse suicidal events and thus could not be iden-
tified as a risk factor. An added confusion is the absence of
procedures for identifying adverse events in a consistent
manner across companies (for trials) and across voluntary
reports in the Medical Dictionary for Regulatory Activities
(MedDRA), the data dictionary for MedWatch [43]. Thus,
activation/agitation/hostility has multiple descriptors in
clinical trials, including hyperkinesis. These events are
more frequent in clinical trials with children than with
adults. For example, in SSRI pediatric trial data, the aver-
age frequency of activation or agitation in children was
10–15% [44]. Recently, the FDA announced that meta-
analysis of adverse psychiatric events in clinical trials of
anticonvulsants for seizure, psychiatric disorders and
other conditions were significantly greater for drug-
treated vs. placebo-treated subjects (0.4% vs. 0.22%).
Whether meta-analysis of data with incomplete historical
data on risk factors such as psychiatric history is adequate
to substantiate increased psychiatric symptoms in major
anticonvulsants for seizure disorder deserves further
assessment [45]. In summary, the lack of standardization
of adverse event reporting in clinical trials [46] limits
comparative safety assessments from trials and argues for
improved adverse drug event monitoring in clinical trials
and for more prospective studies of adverse events in the
post-marketing surveillance phase of drug development
and appraisal.
Systematic clinical monitoring for psychotropic drug safety
The growing use of concomitant psychotropics in U.S.
children [47,48] raises special concerns. Such use is gener-
ally off-label and often without systematic study to assure
either efficacy or safety. To improve the confidence of pre-
scribing physicians in the safety of monotherapy as well as
combination pharmacotherapy, regular monitoring is rec-
ommended. Monitoring refers to collecting and organiz-
ing information systematically with respect to time and
Table 2: Common off-label uses of psychiatric drugs in U.S. youth.*
Class and subclass Drug Off-label use
Stimulants
Modafinil ADHD
Antidepressants
SSRI
Citalopram Depression; Anxiety
Duloxetine Depression; Anxiety
Escitalopram Depression; Anxiety
Paroxetine Depression; Dysthymia; Anxiety; OCD
Sertraline Depression
Other
Bupropion Depression; Anxiety ADHD
Mirtazapine Depression; Sleep
Venlafaxine Depression; Anxiety; ADHD
Antipsychotics
Atypical
Clozapine Psychosis; Bipolar, Behavioral and Tic Disorders; Schizophrenia < 16
Olanzapine Psychosis; Bipolar, Behavioral and Tic Disorders
Quetiapine Psychosis; Bipolar, Behavioral and Tic Disorders; Autism
Ziprasidone Psychosis; Bipolar, Behavioral and Tic Disorders; Autism
Anticonvulsant-Mood Stabilizers
Divalproex Bipolar Disorder; Aggression
Gabapentin Bipolar Disorder
Lamotrigine Bipolar Disorder; Depression
Oxcarbazepine Bipolar Disorder; Aggression
Alpha-Agonists
Clonidine Sleep; ADHD; Aggression; Autism; Tourette's
Guanfacine Sleep; ADHD
*This information was derived from WH Green [6]Child and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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relevance to the issues of concern. Information should be
relevant to potential adverse drug events, effectiveness
and satisfaction so that systematic monitoring is targeted
to serious adverse events which are drug-specific, practical
and timely. For example, for atypical antipsychotics,
before treatment is initiated baseline physical measures
should include body weight [measured as body mass
index (BMI)], liver function tests and lipid measures so
that subsequent treatment-emergent events can be more
accurately associated with drug exposure [49].
European standards for psychotropic drug safety
Most European country health care systems are substan-
tially different than that of the U.S. European health insur-
ance and access to care is usually available for nearly
everyone either in state run systems or by state regulated
health insurance companies. Despite this high standard
for provision of care, many aspects of drug treatment
safety are still neglected. Collecting safety information
from health insurance data and networks to monitor and
report adverse events could be easily regulated and imple-
mented on a national level but still these initiatives rely
Table 3: Suggested adverse event monitoring for selected medications used to treat labeled and unlabeled psychiatric indications in 
children and adolescents
Drug Class Drug Adverse Events Comment; Monitoring tool
Alpha-Agonists Clonidine Guanfacine Bradycardia; Hypotention; Heart 
block
Rule out congenital heart disease; 
Blood pressure and heart rate
Stimulants Amphetamines Serious cardiovascular risk [59] Blood pressure and heart rate; ECG 
where there is a question of 
congenital heart disease
Anticonvulsant-Mood Stabilizer Divalproex; Valproic acid Polycystic ovaries in girls; 
malformation rate of 11.1% 
compared with 3.1% in non-drug 
exposed fetuses [62]; 
hepatotoxicity [63]; pancreatitis 
[64,65]
Discuss risks and provide written 
information before initiating therapy; 
girls of child-bearing age should be 
counseled regarding birth control. 
Close laboratory monitoring of liver 
enzymes & coagulation tests in the 
first 6 months; clinical monitoring for 
vomiting and apathy; blood levels
Lamotrigine Rash requiring hospitalization, 
possible Stevens Johnson Syndrome 
or hypersensitivity syndrome; 
serum concentrations doubled 
when divalproex was added in 
adjunctive treatment of epilepsy.
Indication in those younger than 16 is 
restricted to Lennox Gastaut 
Syndrome. Black box warning for 
potentially life threatening rashes
Antidepressants SSRIs Activation syndrome, suicidality A written diary by the parent of target 
symptoms and selected adverse 
events is useful. Regular contact to 
review information when drug or 
dose is initiated or changed. Monitor 
side effects and response regularly
TCAs Dose-dependent cardiac 
conduction delays; asystole
Baseline and follow-up ECG at 
therapeutic dose, blood levels.
Bupropion Dose-dependent risk of seizure Consider alternatives in youth with a 
history of seizure disorders or bulimia
Atypical Antipsychotics Olanzapine Risperidone 
Quetiapine Clozapine Ziprasidone
Relatively greater weight gain in 
youths than in adults 
Extrapyramidal Side Effects (EPS) 
Hyperprolactinaemia Possible 
Hyperthyroidism (Quetiapine)
Baseline and repeat weight, height and 
waist circumference, serum fasting 
lipid and hepatic enzyme levels, 
thyroid panel (for quetiapine). Fasting 
glucose level monitoring for the risk 
of diabetes; diet and exercise 
management. Monitor quarterly or as 
indicated for movement disorders 
with the Abnormal Involuntary 
Movement Scale (AIMS). Prolactin 
blood level monitoring in the 
presence of abnormal sexual signs and 
symptoms.
Lithium Lithium Thyroid abnormalities; 
nephrotoxicity; renal concentration 
diminution; lithium toxicity
Lithium levels, baseline thyroid panel, 
serum creatinine and urinalysis. 
Repeat periodically, and when dose or 
regimen changes or symptoms suggest 
toxicity.Child and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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on the activities of different insurance companies as
shown in a recent report of the Gmünder Ersatzkasse, a
statutory insurance company in Germany [50].
At the European Union level, The European Agency for
the Evaluation of Medicinal Products (EMEA) is responsi-
ble for the implementation of the European Risk Manage-
ment Strategy (ERMS) [51]. This strategy focuses on
harmonizing European community legislation with
respect to drug safety and thereby strengthening the Euro-
pean Union Drug Regulatory Authorities (EUDRA) vigi-
lance, the population-based EU safety database. There are
plans to introduce a special Eudra Vigilance Dataware-
house and Analysis System to enhance safety surveillance.
In addition to spontaneous reporting of adverse event sys-
tems, a network of centers for pharmacoepidemiology
and pharmacovigliance is planned which should facilitate
the conduct of multicenter studies or authorize safety top-
ics which fall under the European Network of Centres for
Pharmacoepidemiology and Pharmacovigilance (ENCeP
P) and is a major aim of the EMEA.
At the country level, in German adult psychiatry a thera-
peutic drug monitoring network (TDM) was established
[52-54]. Supported by a research grant after preparatory
work by the commission on developmental psychophar-
macology from the German professional societies in child
and adolescent psychiatry in 2008, a child psychiatric
TDM network was founded [55]. This therapeutic drug
monitoring network comprises the measurement of
plasma or serum levels and the documentation of clinical
effectiveness and unwanted side effects. Therapeutic drug
monitoring thus is aiming at defining therapeutic ranges
of plasma or serum levels in order to maximize clinical
effects while minimizing the risk of side effects or toxicity,
particularly in high risk populations e.g., the developing
child. Pilot work showing the high variation of plasma
levels of atypical neuroleptics in children has been pub-
lished [56]. The general need for this network was
described by Gerlach et al. in 2006 [57], and has been
accepted by the boards of the three professional societies
in Germany.
In cases of inpatient treatment with psychotropic drugs,
the German insurance companies pay for therapeutic drug
monitoring as a measure of quality assurance in the field
of pediatric psychopharmacology. In the Future the TDM
model might be extended to large U.S practices using sim-
plified validated adverse drug event monitoring. For
example, in The Child and Adolescent Psychiatry Trials
Network (CAPTN), the practice-based research network in
child psychiatry, the pilot study of Pediatric Adverse
Events Rating Scale (PAERS) [58] could be further vali-
dated by applying European TDM established findings on
plasma level-side effect related data to U.S. youth popula-
tions.
At the most global level, the World Health Organization
(WHO) promotes an international drug monitoring pro-
gram which started operating in 1968. Currently, 86
countries participate in that program. Reported cases are
forwarded from national pharmacovigilance centers to
the WHO collaborating center for international drug
monitoring in Uppsala Sweden. The case reports are
stored in the Adverse Drug Reaction (ADR) database of
the WHO which is the most comprehensive source of
international ADR information. This time-honored sys-
tem notwithstanding, there are significant challenges to
improve the probability of finding serious and rare events
in youth and to rule out long-term adverse effects on
development. The encouraging signs of renewed efforts in
the European Union collaborations are further aided by
the advent of powerful computing systems and suggest
that psychopharmacologic drug safety in children is pro-
gressing.
Recommended baseline and ongoing monitoring of 
children and adolescents
A comprehensive assessment of health status (rating of
symptoms and impairment) should be conducted before
introducing psychotropic medications, whether utilized
for labeled or off-label uses [6]. A comprehensive assess-
ment at baseline includes physical measures such as pulse,
respiration rate and blood pressure. Regular assessment of
growth over time using standardized growth charts is rec-
ommended, including measures of height, weight (calcu-
lation of BMI) and with medications where weight gain is
of concern waist circumference. Depending on the phar-
macotherapy, a laboratory panel including complete
blood count, urinalysis, blood urea nitrogen (BUN) level,
serum electrolytes and liver function tests may be indi-
cated. Such data would lessen post hoc conjecture regard-
ing underlying physical abnormalities and the attribution
of emergent adverse drug events. More importantly, it
could improve the close monitoring of preexisting abnor-
mal lab values or of organ function and lead to earlier
interventions to reduce risks associated with drug-related
events or drug interactions. Which laboratory assessments
are indicated depends upon presenting symptoms as well
as the selection of medication to be initiated. In addition,
an electrocardiogram (ECG) may be appropriate when
there is concern about potential changes in cardiac con-
duction, such as when a TCA is initiated. By establishing a
baseline battery of physical health status, subsequent
changes can be accurately assessed in terms of treatment-
emergent adverse drug events.
The rationale for drug class-specific monitoring includes
the following:Child and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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￿ Amphetamines. The growth in use of amphetamines
since the marketing of Adderall® is substantial with as
much as half of U.S. stimulant use in youth now repre-
senting exposure to amphetamine salts rather than to
methylphenidate. Consequently, recent concerns about
cardiac risks from FDA analysis of MedWatch data sparked
controversy [59] and Canadian agency reports of cardiac
deaths raised a similar concern [60]. Until the issue is laid
to rest, the value of baseline cardiac assessment to rule out
the likelihood of cardiac abnormalities may be prudent
[6].
￿ Alpha-Agonists. Clonidine and guanfacine were
approved for adult treatment of hypertension. Since 1987,
these drugs have been used off-label in pediatrics for the
treatment of ADHD, to reduce stimulant rebound and
induce sleep. Baseline evidence of cardiovascular health
status is useful to permit adverse symptoms following
drug initiation to be linked to the medication [6] and to
avoid use in those with congenital cardiac anomalies.
• Anticonvulsant-Mood Stabilizers
 Divalproex and Valproic Acid. Valproate treatment initi-
ated in women before the age of 20 had significantly
increased risk of polycystic ovaries [61]. In addition, the
occurrence of an 11.1% malformation rate in drug-treated
compared with 3.1% in non-drug exposed fetuses has
been reported [62]. Ongoing reports of hepatotoxicity
even in youth older than 2 years of age and particularly in
those with concomitant drugs that are liver metabolized
warrant attention [63] as well as pancreatitis among youth
with chronic exposure [64,65].
 Lamotrigine has been reported to have a higher risk of
rash in children than adults [66]. Trial data demonstrated
Stevens Johnson Syndrome, a serious rash often requiring
hospitalization, and hypersensitivity syndrome occurred
in 1% of children and in 0.3% of adults. Serum concentra-
tions doubled when divalproex was added in adjunctive
treatment of epilepsy.
• Antidepressants
 SSRI suicidality (ideation, attempts) was noted in an
average of 4% of of children and adolescents treated with
antidepressants in clinical trials reviewed by regulatory
agencies [67]; other psychiatric adverse effects e.g., behav-
ioral disinhibition, emotionality, activation, irritability,
agitation have been found in up to 25% of children
treated with SSRIs [68]; psychiatric adverse effects are
more common in depressed youth less than 12 years old
than in adolescents [41].
 TCA Dose-dependent cardiac conduction delays; asys-
tole in high dose [6].
 Bupropion. The risk of dose-dependent seizures may
suggest use of an alternative antidepressant to treat youth
with a history of seizure disorder or bulimia.
￿ Atypical Antipsychotics. Relatively greater weight gain
develops in youth than in adults [69] so that baseline and
repeat weight, height and waist circumference should be
measured. Because of the risk of metabolic syndrome,
fasting glucose level monitoring for the onset of diabetes
is warranted [49] as well as liver function and lipid tests.
Diet and exercise management are useful, in light of the
increased risk of weight gain. To assess adverse effects in
clinical practice settings, a revised computerized version
of the NIMH-developed DOTES psychopharmacologic
monitoring scale was used. Extrapyramidal side effects
including rigidity, tremor, and dystonia were seen in 5%
to 15% of youth treated with olanzapine as well as risperi-
done [70].
￿ Lithium has a narrow therapeutic range which empha-
sizes the importance of educating parents and youth as to
the need for adequate hydration and risks of exposure to
situations where excessive sweating may occur (i.e. partic-
ipating in sports, spending time in the heat outdoors), or
if the child experiences significant diarrhea, in order to
avoid toxicity. Baseline and repeat assessment of thyroid
function as well as kidney function during use is recom-
mended [71]. Laboratory assessment of lithium levels is
helpful to avoid toxicity.
• Miscellaneous
 Desmopressin. Recently, an FDA alert warned of severe
hyponatremia and seizures in children treated with intra-
nasal formulations of desmopressin (DDAVP) for primary
nocturnal enuresis. The nasal product is no longer indi-
cated for primary nocturnal enuresis and oral formula-
tions should not be used during acute illnesses which may
lead to fluid and/or electrolyte imbalance [72].
Periodic and ongoing monitoring for safety and 
effectiveness
After initiating drug therapy, safety assessments at regular
intervals are useful to observe the ongoing impact of med-
ication use (Table 3). Column 4 lists specific monitoring
suggestions. More detailed schedules for monitoring can
be found in Correll and Carlson [49]. Dose adjustments
and the addition or withdrawal of concomitant drug ther-
apy can be occasions for biological status checks with lab-
oratory assessments and vital signs, in addition to
assessing drug-specific adverse events.
School performance and social development are measures
of the effectiveness of treatment on overall functioning,
and the patient's or parent's report of adherence is vital to
this assessment and may in part reflect the level of satisfac-Child and Adolescent Psychiatry and Mental Health 2008, 2:24 http://www.capmh.com/content/2/1/24
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tion. When cognitive or emotional symptoms show a lack
of improvement or deterioration, an assessment of the
temporal pattern of drug usage, dosage change and poten-
tial drug-drug interactions can assist in establishing
whether behavioral toxicity, i.e. iatrogenic psychiatric
symptoms, is a likely explanation. This could lead to the
need for discontinuation of the psychotropic medication
responsible for behavioral adverse events.
Discussion
This selective review of pediatric medical and psychiatric
drug usage illustrates the role of clinical monitoring as a
routine aspect of post-marketing surveillance. Distinc-
tions between off-label and labeled indications indicate
that the majority of pediatric psychotropic use is off-label
and supports close monitoring to assure adequate safety.
Until all drugs are properly studied in the populations for
which they are being used, it will be necessary for practi-
tioners to prescribe off-label drugs. Additionally, it is
sometimes necessary to utilize products that have uncer-
tain efficacy and unresolved safety questions, even when
such issues raise serious ethical and clinical considera-
tions. The particular medical circumstances will dictate
what clinical criteria and monitoring are most appropri-
ate. An adequate diagnostic assessment and the establish-
ment of sound baseline data are always mandatory. In
addition, particular attention must be paid to the ethical
considerations generated by clinical decisions to use off-
label treatments, particularly where the evidence of effi-
cacy is weak or anecdotal, and safety signals are unre-
solved. We believe the 1979 Belmont Report on ethical
guidelines for the protection of human subjects of bio-
medical and behavioral research with its associated prin-
ciples could provide an ethical framework for off-label
usage in children in clinical practice [73]. Examining the
issue of off-label use from the perspective of child-patient,
parent-caregiver and prescribing physician offers a sound
approach to the application of these principles. Armed
with a better sense of history and ethics, practitioners in
pediatrics and child psychiatry can provide safer treat-
ments as we build a stronger evidence base for their use.
Conclusion
This historical review presented examples of serious pedi-
atric drug safety problems in the post-marketing phase of
utilization and identified off-label psychiatric use. As a
broad survey of pediatric psychiatric pharmacotherapy, it
provides evidence to support changes in the way we mon-
itor newly approved or off-label drugs for emotional and
behavioral conditions in youth. Since there is less cer-
tainty about the outcome of these medications in children
and adolescents (particularly in concomitant drug regi-
mens), close clinical monitoring is critical to detect
adverse physical and mental changes as well as to ascer-
tain if there is ongoing reduction of symptoms and
improved functioning. This approach would minimize
ineffective treatments that expose youth to drugs of uncer-
tain or unknown risks.
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